Lower costs for lifesaving treatment coming to Oregon in 2026
The OHP is Oregon's Medicaid program, offering coverage for healthcare services. The implementation of this new cut to costs will help those who are covered under OHP and are seeking treatment for a rare or severe disease.
35 states, including Oregon, applied to the Centers for Medicare and Medicaid Services' (CMS) 'Cell and Gene Therapy Access Model' (CGT), designed to lower costs to patients in need as well as the states offering these services. The plan intends to begin by focusing on sickle cell disease, a condition in which red blood cells are misshapen due to a gene mutation.
OSU falls victim to budget cuts, putting a damper on scientific research
This disease is genetic and disproportionately affects those with African ancestry, with 9 of 10 of those affected by the disease identifying as Black. The condition can cause extreme health difficulties.
Emma Sandoe, Medicaid Director for Oregon Health Authority, said, 'The cost of cell and gene therapies for sickle cell disease is a real barrier that prevents Oregonians from living longer, healthier.'
The CGT program will also help patients in preparation for cell therapy. Before the therapy, patients undergo myeloablative chemotherapy, a process that can affect future fertility. CGT will cover, or drastically reduce the cost of, fertility preservation treatments as well as travel expenses and much more.
'This initiative is a big step forward in promoting innovative treatments and increasing access to lifesaving treatment,' Sandoe said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
4 minutes ago
- USA Today
Trump, tech giants want to make it easier to share health records: What it means for you
President Donald Trump and his top health officials are pursuing a new initiative that will allow people to share their personal health and medical records with doctors and hospitals. Technology giants Apple, Amazon, Google and Open AI as well as health industries companies UnitedHealth Group and CVS Health are among more than 60 companies that have agreed to develop standards to share health information across computer systems. Trump touted the idea of eliminating redundancies such as filling out paperwork at multiple health providers offices. "This will allow patients to easily transmit information from one doctor to another," Trump said during a July 30 briefing with Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare & Medicaid Services Administrator Mehmet Oz. Trump emphasized the initiative will be voluntary and require patients to opt in. He added there will be no centralized, government-run database storing patients' personal records. "People are very concerned about the personal records," Trump said. "That's their choice ... it will be absolutely quiet." Large hospital systems and some doctors allow patients to share health information, fill out forms and schedule appointments through websites and mobile apps. And health tech companies have developed apps that allow people to track their health information, but these apps often can't access medical records from health providers, said Amy Gleason, acting administrator of the Department of Government Efficiency, or DOGE. Companies operating 21 networks have agreed to an "interoperability framework" to meet Centers for Medicare & Medicaid Services criteria, according to the Trump administration. Hospital systems and electronic health records vendors have agreed to cooperate in the effort, according to CMS. Participating apps would help people manage obesity and diabetes, including the use of AI assistants to help check symptoms or schedule appointments, CMS said. Privacy, data security remain top worries The health care industry and tech companies have been attempting to reduce paperwork and seamlessly share electronic health records for three decades, said Chris Pierson, CEO of BlackCloak, an Orlando, Florida-based cybersecurity company. Hospitals, doctors, labs and vendors that directly handle such sensitive medical records are subject to a federal privacy law, called the Health Insurance Portability and Accountability Act, or HIPAA. To make health information and records more portable and accessible, consumers need to be guaranteed strong privacy protections and granted control over what information is shared, Pierson said. A consumer might be willing to share their sensitive information with doctors, hospitals or labs. But the same person might want to block an app from sharing records with third parties such as exercise equipment vendors or nutritional supplement retailers. Pierson said such apps would likely still need to comply with HIPAA and other federal and state laws. Given that the apps are voluntary and require consent, they likely would comply with privacy laws, Pierson said. Companies also would need to safeguard information technology security to protect the sensitive information from data breaches. Hackers target health records Digital medical records are a popular target for hackers seeking sensitive health information, bank records and a person's identifiable information such as dates of birth and Social Security numbers. The number of attacks has surged in recent years and are often carried out by organized hackers, often operating overseas, who target the computer systems of health providers and the vendors and companies that serve them. HHS investigates whether breaches involve violations of health information privacy and security laws and publicly reports attacks that affect 500 or more on its website. In July alone, more than two dozen data breaches compromised the records of more than 3 million people, HHS records show. The largest hack in recent years involved the February 2024 attack on UnitedHealth-owned subsidiary Change Healthcare. The attack disrupted the health care industry because doctors and hospitals were unable to collect payments for weeks when computer systems went down.
Yahoo
2 hours ago
- Yahoo
Trump demands pharma CEOs lower drug prices within 60 days
-- President Donald Trump has sent letters to the CEOs of 17 pharmaceutical companies demanding action to address high prescription drug costs in the United States, the White House announced Thursday. Trump shared the letters sent to major pharmaceutical firms including Regeneron (NASDAQ:REGN), Merck (NSE:PROR), AstraZeneca (NASDAQ:AZN), GSK, Pfizer (NYSE:PFE), Novo Nordisk (NYSE:NVO), Amgen (NASDAQ:AMGN), Bristol-Myers, AbbVie (NYSE:ABBV), Novartis (SIX:NOVN), Johnson & Johnson (NYSE:JNJ), Genentech, EMD Serono, Boehringer Ingelheim, and Gilead (NASDAQ:GILD) on his Truth Social platform. In the letters, Trump referenced his May 12, 2025 Executive Order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," which aims to ensure Americans pay the same prices for medications as other developed nations. The President noted that brand name drug prices in the U.S. are currently up to three times higher on average than in other countries for identical medicines. Trump called on pharmaceutical manufacturers to take four specific actions within the next 60 days, by September 29, 2025: First, extend Most-Favored-Nation (MFN) pricing to Medicaid patients for their full portfolio of existing drugs. Second, guarantee MFN pricing for newly launched drugs for Medicare, Medicaid, and commercial payers both at launch and going forward. Third, return increased revenues from abroad to American patients and taxpayers, with Trump stating that U.S. trade policy would support manufacturers in negotiating harder with "foreign freeloading nations." Fourth, participate in Direct-to-Consumer and Direct-to-Business distribution models for high-volume, high-rebate prescription drugs to ensure all Americans receive the same low MFN prices. The President warned pharmaceutical companies that if they refuse to cooperate, his administration would "deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices." Trump stated that his team, including Secretary Kennedy and Administrator Oz, are ready to implement these terms and expect immediate good faith engagement from the companies. Related articles Trump demands pharma CEOs lower drug prices within 60 days Apollo economist warns: AI bubble now bigger than 1990s tech mania If Powell goes, does Fed trust go with him?
NBC News
2 hours ago
- NBC News
Trump gives drugmakers 60 days to slash prescription drug prices
President Donald Trump sent letters to more than a dozen major drugmakers Thursday demanding that they lower the cost of prescription drugs in the U.S. within 60 days. In the letters — which Trump published on his social media platform Truth Social — the drugmakers were told to offer the 'full portfolio' of their existing medications to Medicaid patients at the same prices paid abroad, also known as the 'most favored nation' rule. He also told drugmakers to 'guarantee' that patients on Medicare, Medicaid and private insurance get the same lower prices that are paid abroad for all newly approved drugs 'both upon launch and moving forward.' He also demanded that drugmakers return any additional revenues earned abroad to U.S. taxpayers, and create a 'direct to consumer' option for certain medications that would also be offered at lower prices. 'Make no mistake: a collaborative effort towards achieving global pricing parity would be the most effective path for companies, the government, and American patients,' Trump wrote in the letters. 'But if you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices.' It's unclear, experts say, whether Trump has the authority to force drugmakers to lower the cost of their prescription drugs without the help of Congress. What's more, any attempt to do so is likely to be met with fierce pushback from the drug industry. 'It may take more than a tough letter from the President to motivate the pharmaceutical industry to drop their prices,' said Tricia Neuman, executive director of the program on Medicare policy at KFF, a nonpartisan health policy research group. 'The voluntary approach hasn't worked so far to drive down drug prices,' she added. 'Drug prices tend to go down when compelled by law or in response to competition.' Trump has repeatedly complained — during both terms — that people in the U.S. pay far more for prescription drugs than people in other countries. Indeed, prescription drug prices in the United States are notoriously high — up to 10 times more than in other nations of similar size and wealth, according to the Rand Corp., a public policy think tank. More than 3 in 4 adults in the U.S. say the cost of medications is unaffordable, according to a poll from KFF. In May, Trump signed an executive order instructing federal health officials to renew an effort to implement the 'most favored nation' rule — a strategy he pursued unsuccessfully during his first term. The 17 letters were sent Thursday to major drugmakers such as Eli Lilly, GSK, Pfizer, Merck, Johnson & Johnson, Amgen, Novo Nordisk and Novartis. NBC News has reached out to all 17 companies for comment. A spokesperson for Novo Nordisk said the company 'remains focused on improving patient access and affordability, and we will continue to work to find solutions that help people access the medication they need.' A spokesperson for Johnson & Johnson said the company was still reviewing the letter, and referred NBC News to the pharmaceutical industry's top lobbying group, PhRMA, for comment. PhRMA did not immediately respond to a request for comment. The Trump administration does have another tool at its disposal to lower the cost of prescription drugs: Medicare drug pricing negotiations. Signed into law by President Joe Biden through the Inflation Reduction Act, the provision allows Medicare to negotiate prices on the costliest medications. The first round of negotiations is estimated to save Medicare $6 billion in 2026, when the prices are expected to go into effect.
